REGULATORY-ADAPTIVE STATE IN EVALUATION OF BISOPROLOL AND NEBIVOLOL THERAPY EFFECTIVENESS FOR VENTRICULAR ARRHYTHMIA

Aim. To compare efficacy of bisoprolol and nebivolol treatment in ventricular arrhythmias patients (VA) and arterial hypertension (AH) and/ or ischemic heart disease (IHD) taken its influence on regulatoryadaptive state (RAS).Material and methods. Totally, 60 patients participated with VA of Lown I-IV grades, Bigger II-III grades, at the background of AH II-III stage and/or IHD, who were randomized to 2 groups of treatment: bisoprolol 6,5±1,8 mg daily or nebivolol 6,5±2,1 mg daily. As combination therapy, lisinopril was used 12,3±4,0 mg daily and 13,7±4,5 mg/daily, acetylsalicylic acid 92,3±18,8 mg/daily and 92,9±18,2 mg/daily, atorvastatin 16,3±4,8 mg/daily and 16,5±4,7 mg daily together with bisprolol or nebivolol, respectively. At baseline and in 6 months of therapy we performed: quantitative RAS assessment via the test of cardio-respiratory synchronicity, echocardiography, triplex scanning of brachocephalic arteries, tredmill, six minute walking test, 24-hour blood pressure monitoring and ECG monitoring, self-assessed life quality.Results. Both regimens of combination therapy comparably same improved structural and functional state of the heart, decreased blood pressure, effectively suppressed ventricular arrhythmia. However, only nebvolol positively influenced RAS, better improved exercise tolerance and improved life quality.Conclusion. In VA patients with AH of II-III stages and/or IHD, usage of nebivolol, comparing to bisoprolol, as combination therapy, might be more preferrable due to positive influence on RAS.